4//SEC Filing
Cohen David E 4
Accession 0001562180-20-001614
CIK 0001557883other
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 7:31 PM ET
Size
26.1 KB
Accession
0001562180-20-001614
Insider Transaction Report
Form 4
Dermira, Inc.DERM
Cohen David E
Director
Transactions
- Disposition to Issuer
Director Stock Stock Option (Right to buy)
2020-02-20−8,620→ 0 totalExercise: $0.99Exp: 2021-10-03→ Common Stock (8,620 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-02-20−10,344→ 0 totalExercise: $16.00Exp: 2025-06-10→ Common Stock (10,344 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-02-20−10,344→ 0 totalExercise: $28.82Exp: 2026-06-20→ Common Stock (10,344 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-02-20−6,000→ 0 totalExercise: $28.01Exp: 2027-06-12→ Common Stock (6,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-02-20−6,000→ 0 totalExercise: $9.95Exp: 2028-06-12→ Common Stock (6,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-02-20−6,000→ 0 totalExercise: $9.38Exp: 2029-06-03→ Common Stock (6,000 underlying) - Disposition to Issuer
Common Stock
2020-02-20$18.75/sh−35,682$669,038→ 0 total - Disposition to Issuer
Director Stock Stock Option (Right to buy)
2020-02-20−17,241→ 0 totalExercise: $0.99Exp: 2021-10-03→ Common Stock (17,241 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-02-20−14,224→ 0 totalExercise: $5.51Exp: 2024-06-05→ Common Stock (14,224 underlying) - Disposition to Issuer
Restricted Stock Unit
2020-02-20−3,000→ 0 total→ Common Stock (3,000 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
- [F2]Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
- [F3]Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Documents
Issuer
Dermira, Inc.
CIK 0001557883
Entity typeother
Related Parties
1- filerCIK 0001347383
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 7:31 PM ET
- Size
- 26.1 KB